Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drugs for pre-osteoporosis: prevention or disease mongering?

Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal: JAMA Date: 1999-08-18 Impact factor: 56.272

6. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal: JAMA Date: 2003-05-14 Impact factor: 56.272

7. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.

Authors: John A Kanis; Olof Johnell; Dennis M Black; Robert W Downs; Somnath Sarkar; Thomas Fuerst; Roberta J Secrest; Imre Pavo
Journal: Bone Date: 2003-09 Impact factor: 4.398

8. An approach to identifying osteopenic women at increased short-term risk of fracture.

Authors: Paul D Miller; Suna Barlas; Susan K Brenneman; Thomas A Abbott; Ya-Ting Chen; Elizabeth Barrett-Connor; Ethel S Siris
Journal: Arch Intern Med Date: 2004-05-24

9. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors: D Marshall; O Johnell; H Wedel
Journal: BMJ Date: 1996-05-18

10. Effects of risedronate on fracture risk in postmenopausal women with osteopenia.

Authors: E S Siris; J A Simon; I P Barton; M R McClung; A Grauer
Journal: Osteoporos Int Date: 2007-10-30 Impact factor: 4.507

16 in total

Review 1. Assessment of fracture risk.

Authors: Sanford Baim; William D Leslie
Journal: Curr Osteoporos Rep Date: 2012-03 Impact factor: 5.096

2. [Should we change our attitude on postmenopausal hormone replacement therapy?].

Authors: Alberto López García-Franco; Pablo Alonso Coello; Isabel del Cura González; Julia Ojuel Solsona; Lorenzo Arribas Mir; Mercè Fuentes Pujol; Emilia Bailón Muñoz; Blanca Gutierrez Teira; María José Iglesias Piñeiro; Jacinta Landa Goñi
Journal: Aten Primaria Date: 2009-05-29 Impact factor: 1.137

3. Legal liability in bisphosphonate-related osteonecrosis of the jaw.

Authors: L Lo Russo; D Ciavarella; C Buccelli; O Di Fede; G Campisi; L Lo Muzio; G Pellegrino; P Di Lorenzo
Journal: Br Dent J Date: 2014-09 Impact factor: 1.626

4. Personalised medicine, disease prevention, and the inverse care law: more harm than benefit?

Authors: Jack E James
Journal: Eur J Epidemiol Date: 2014-04-12 Impact factor: 8.082

5. Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy.

Authors: Benjamin Chin-Yee; S V Subramanian; Amol A Verma; Andreas Laupacis; Fahad Razak
Journal: Milbank Q Date: 2018-06 Impact factor: 4.911

6. Hormone replacement therapy advertising: sense and nonsense on the web pages of the best-selling pharmaceuticals in Spain.

Authors: Elisa Chilet-Rosell; Marta Martín Llaguno; María Teresa Ruiz Cantero; Pablo Alonso-Coello
Journal: BMC Public Health Date: 2010-03-16 Impact factor: 3.295

Drugs for pre-osteoporosis: prevention or disease mongering?

1. Osteoporosis in postmenopausal women: diagnosis and monitoring.

2. The relationship between bone density and incident vertebral fracture in men and women.

3. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes.

Review 4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

5. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.